Sign Up Today and Learn More About Adaptive Phage Therapeutics Stock
Invest in or calculate the value of your shares in Adaptive Phage Therapeutics or other pre-IPO companies through EquityZen's platform.
Adaptive Phage Therapeutics Stock
Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria.
About Adaptive Phage Therapeutics Stock
Founded
2016
Headquarters
Bethesda, MD, US
Industries
Science and Engineering, Health Care, Biotechnology
Adaptive Phage Therapeutics Press Mentions
Stay in the know about the latest news on Adaptive Phage Therapeutics
Shareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage Therapeutics
morningstar • Mar 07, 2024
Adaptive Phage Therapeutics Raises Further $20M; Extends Series B to $61M
finsmes • Apr 04, 2022
Adaptive Phage Therapeutics Appoints Michele Wales, Ph.D., J.D., as Chief Legal Officer
biospace • Sep 23, 2021
Navy licenses offer new hope for patients suffering from antibiotic-resistant infections
techlinkcenter • Feb 22, 2021
Phage Therapy Firm APT Lands DoD Contract for Antibiotic Alternative
xconomy • Jan 16, 2020
Adaptive Phage Therapeutics Management
Leadership team at Adaptive Phage Therapeutics
Co-Founder & CEO
Gregory L. Merril
Co-Founder and CSO
Carl Merril
Join now and verify your accreditation status to gain access to:
- Adaptive Phage Therapeutics current valuation
- Adaptive Phage Therapeutics stock price
- Available deals in Adaptive Phage Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Adaptive Phage Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Adaptive Phage Therapeutics through EquityZen funds. These investments are made available by existing Adaptive Phage Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Adaptive Phage Therapeutics stock?
Shareholders can sell their Adaptive Phage Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
